The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation

Journal of Cellular Biochemistry

Volumn 111, Issue 4, 2010, Pages 933-943

  Li, Xiaodong ^a   McGee Lawrence, Meghan E ^a   Decker, Matthew ^a   Westendorf, Jennifer J ^a  

^a MAYO CLINIC   (United States)

Author keywords

AML 3; Bmp2; Cbfa1; Ets; EWSR1; FLI1; PEBP2aA

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; EWING SARCOMA FUSION PROTEIN; HYBRID PROTEIN; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING COMPETITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; CELL STRAIN HEK293; CELL STRUCTURE; CHILD; CONTROLLED STUDY; EWING SARCOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MULTIPOTENT STEM CELL; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR CELL;

AMINO ACID SEQUENCE; ANIMALS; CALMODULIN-BINDING PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SHAPE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; HUMANS; MESENCHYMAL STEM CELLS; MICE; ONCOGENE PROTEINS, FUSION; OSTEOBLASTS; PROTEIN BINDING; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEIN C-FLI-1; SARCOMA, EWING'S; TRANSCRIPTION, GENETIC;

EID: 78049248010     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22782     Document Type: Article

References (43)

1. Afzal F, Pratap J, Ito K, Ito Y, Stein JL, van Wijnen AJ, Stein GS, Lian JB, Javed A. 2005. Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol 204: 63-72.
2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, Aurias A, Thomas G. 1992. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165.
3. Eliazer S, Spencer J, Ye D, Olson E, Ilaria RL, Jr. 2003. Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol Cell Biol 23: 482-492.
4. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, Toretsky JA. 2009. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 15: 750-756.
5. Erkizan HV, Uversky VN, Toretsky JA. 2010. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin Cancer Res 16: [Epub ahead of print].
6. Ewing J. 1921. Diffuse endothelioma of bone. Proc New York Pathol Soc 21: 17-24.
7. Fowler M, Borazanci E, McGhee L, Pylant SW, Williams BJ, Glass J, Davis JN, Meyers S. 2005. RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem. 97: 1-17.
8. Hancock JD, Lessnick SL. 2008. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 7: 250-256.
9. Hoeppner LH, Secreto F, Jensen ED, Li X, Kahler RA, Westendorf JJ. 2009. Runx2 and bone morphogenic protein 2 regulate the expression of an alternative Lef1 transcript during osteoblast maturation. J Cell Physiol 221: 480-489.
10. Huang H, Yu M, Akie TE, Moran TB, Woo AJ, Tu N, Waldon Z, Lin YY, Steen H, Cantor AB. 2009. Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. Mol Cell Biol 29: 4103-4115.
11. Javed A, Bae JS, Afzal F, Gutierrez S, Pratap J, Zaidi SK, Lou Y, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2008. Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal. J Biol Chem 283: 8412-8422.
12. Javed A, Afzal F, Bae JS, Gutierrez S, Zaidi K, Pratap J, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2009. Specific residues of RUNX2 are obligatory for formation of BMP2-induced RUNX2-SMAD complex to promote osteoblast differentiation. Cells Tissues Organs 189: 133-137.
13. Jedlicka P. 2010. Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol 3: 338-347.
14. Jensen ED, Niu L, Caretti G, Nicol SM, Teplyuk N, Stein GS, Sartorelli V, van Wijnen AJ, Fuller-Pace FV, Westendorf JJ. 2008. p68 (Ddx5) interacts with Runx2 and regulates osteoblast differentiation. J Cell Biochem 103: 1438-1451.
15. Jensen ED, Gopalakrishnan R, Westendorf JJ. 2010. Regulation of gene expression in osteoblasts. Biofactors 36: 25-32.
16. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, Kovar H. 2009. A molecular function map of Ewing's sarcoma. PLoS ONE 4: e5415.
17. Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL. 2009. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res. 69: 9047-9055.
18. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764.
19. Kovar H. 2005. Context matters: The hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 15: 189-196.
20. Law WJ, Cann KL, Hicks GG. 2006. TLS, EWS and TAF15: A model for transcriptional integration of gene expression. Brief Funct Genomic Proteomic 5: 8-14.
21. Li V, Raouf A, Kitching R, Seth A. 2004. Ets2 transcription factor inhibits mineralization and affects target gene expression during osteoblast maturation. In Vivo 18: 517-524.
22. Li X, Hoeppner LH, Jensen ED, Gopalakrishnan R, Westendorf JJ. 2009. Co-activator activator (CoAA) prevents the transcriptional activity of Runt domain transcription factors. J Cell Biochem 108: 378-387.
23. Li X, Decker M, Westendorf JJ. 2010. TEThered to Runx: Novel binding partners for runx factors. Blood Cells Mol Dis 45: 82-85.
24. Liao J, McCauley LK. 2006. Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 25: 559-571.
25. Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM, Lozano G. 2008. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 68: 8968-8975.
26. Miyagawa Y, Okita H, Itagaki M, Toyoda M, Katagiri YU, Fujimoto J, Hata J, Umezawa A, Kiyokawa N. 2009. EWS/ETS regulates the expression of the Dickkopf family in Ewing family tumor cells. PLoS ONE 4: e4634.
27. Nowling TK, Fulton JD, Chike-Harris K, Gilkeson GS. 2008. Ets factors and a newly identified polymorphism regulate Fli1 promoter activity in lymphocytes. Mol Immunol 45: 1-12.
28. Olmos D, Tan DS, Jones RL, Judson IR. 2010. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: Twenty years from the bench to the bedside. Cancer J 16: 183-194.
29. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89: 765-771.
30. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
31. Prieur A, Tirode F, Cohen P, Delattre O. 2004. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24: 7275-7283.
32. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A, Stamenkovic I. 2005. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65: 11459-11468.
33. Rossow KL, Janknecht R. 2001. The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res 61: 2690-2695.
34. Sato M, Morii E, Komori T, Kawahata H, Sugimoto M, Terai K, Shimizu H, Yasui T, Ogihara H, Yasui N, Ochi T, Kitamura Y, Ito Y, Nomura S. 1998. Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene 17: 1517-1525.
35. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, Afar D, Burdach SE. 2004. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 64: 8213-8221.
36. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, Suva D, Clement V, Provero P, Cironi L, Osterheld MC, Guillou L, Stamenkovic I. 2009. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 69: 1776-1781.
37. Tan AY, Manley JL. 2009. The TET family of proteins: Functions and roles in disease. J Mol Cell Biol. 1: 82-92.
38. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. 2007. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11: 421-429.
39. Toomey EC, Schiffman JD, Lessnick SL. 2010. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene [Epub ahead of print].
40. Torchia EC, Jaishankar S, Baker SJ. 2003. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res 63: 3464-3468.
41. Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, Thiery JP, Olschwang S, Philip I, Berger MP, Philip T, Lenoir GM, Mazabrand A. 1988. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 32: 229-238.
42. Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, Reynolds CP, Rosen N. 1990. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 86: 1806-1814.
43. Zeng C, McNeil S, Pockwinse S, Nickerson J, Shopland L, Lawrence JB, Penman S, Hiebert S, Lian JB, van Wijnen AJ, Stein JL, Stein GS. 1998. Intranuclear targeting of AML/CBFalpha regulatory factors to nuclear matrix-associated transcriptional domains. Proc Natl Acad Sci USA 95: 1585-1589.